BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes

• Sultan Abdul-Jawad,
• Richard Beatson,
• Thomas Lechmere,
• Rosalind Graham,
• Thanussuyah Alaguthurai,
• Carl Graham,
• Jennifer Vidler,
• Austin Kulasekararaj,
• Piers E.M. Patten,
• Katie J. Doores,
• Sheeba Irshad

Affiliations

Sultan Abdul-Jawad

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK

Richard Beatson

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK

Thomas Lechmere

Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, UK

Rosalind Graham

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK

Thanussuyah Alaguthurai

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Breast Cancer Now Research Unit, King’s College London, London, UK

Carl Graham

Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, UK

Jennifer Vidler

Department of Haematological Medicine, King’s College Hospital, London, UK

Austin Kulasekararaj

Department of Haematological Medicine, King’s College Hospital, London, UK

Piers E.M. Patten

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Department of Haematological Medicine, King’s College Hospital, London, UK

Katie J. Doores

Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, UK

Sheeba Irshad

Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Breast Cancer Now Research Unit, King’s College London, London, UK; Guy’s and St Thomas’ NHS Foundation Trust, London, UK; Cancer Research UK (CRUK) Clinician Scientist, London, UK